MedTrace Logo

Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

NCT04939935 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1174

Last updated 2026-03-31

No results posted yet for this study

Summary

This study will investigate if a medication (metformin) widely used in the treatment of diabetes could be re-purposed for the treatment of patients with a diagnosis of early stage ADPKD to slow the rate of kidney function decline, reducing morbidity and mortality and improving the quality of life for ADPKD patients.

Conditions

  • Autosomal Dominant Polycystic Kidney Disease

Interventions

DRUG

Metformin XR

Extended release metformin.

OTHER

Control

Placebo is inactive tablets that is identical to the intervention Metformin tablets.

Sponsors & Collaborators

  • The University of Queensland

    lead OTHER

Principal Investigators

  • Andrew Mallett, MBBS, PhD · Townsville University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-29
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • Australia
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04939935 on ClinicalTrials.gov